NASDAQ:SRZN Surrozen Q3 2024 Earnings Report $29.54 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$29.94 +0.40 (+1.35%) As of 09/25/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Surrozen EPS ResultsActual EPS-$0.44Consensus EPS -$2.77Beat/MissBeat by +$2.33One Year Ago EPSN/ASurrozen Revenue ResultsActual Revenue$10.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASurrozen Announcement DetailsQuarterQ3 2024Date11/6/2024TimeBefore Market OpensConference Call DateTuesday, November 5, 2024Conference Call Time6:00PM ETUpcoming EarningsSurrozen's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Surrozen Earnings HeadlinesSurrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 23, 2026 | americanbankingnews.comSurrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents.September 28 at 1:00 AM | Brownstone Research (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)September 11, 2026 | theglobeandmail.comSurrozen Submits IND Application For SZN-8141 In Diabetic Macular EdemaSeptember 8, 2026 | rttnews.comSurrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaSeptember 8, 2026 | globenewswire.comSee More Surrozen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email. Email Address About SurrozenSurrozen (NASDAQ:SRZN) is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body. The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression. Its pipeline has included candidates such as SZN-043, SZN-1326 and SZN-413, which have been studied or developed for selected inflammatory, fibrotic and regenerative indications. Surrozen was founded to translate advances in Wnt biology into medicines and became a publicly traded company on the Nasdaq under the symbol SRZN. As a development-stage biotechnology company, it has concentrated primarily on research, clinical development and partnerships rather than commercial product sales. The company’s programs remain subject to clinical, regulatory and funding risks typical of the biotechnology industry.View Surrozen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
